Novartis

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate.

CEO

Vasant Narasimhan

CEOVasant Narasimhan

Employees

76,057

Employees76,057

Headquarters

Basel, Basel-Stadt (Basle Town)

HeadquartersBasel, Basel-Stadt (Basle Town)

Founded

1996

Founded1996

Employees

76,057

Employees76,057

NVS Key Statistics

Market cap

212.19B

Market cap212.19B

Price-Earnings ratio

13.35

Price-Earnings ratio13.35

Dividend yield

3.23%

Dividend yield3.23%

Average volume

2.07M

Average volume2.07M

High today

$98.22

High today$98.22

Low today

$97.44

Low today$97.44

Open price

$97.67

Open price$97.67

Volume

1.40M

Volume1.40M

52 Week high

$108.78

52 Week high$108.78

52 Week low

$89.00

52 Week low$89.00

NVS News

Quartz 2d

Pharma sales outperform Wall Street expecations - Quartz

It has been a busy week for pharma giants reporting their latest quarterly earnings and a lot of them have exceeded analysts’ estimates. HGTV's Property Brot...

Investor's Business Daily 2d

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market

Novartis (NVS) blazed a trail for treating cancer with targeted radiopharmaceuticals, a treatment that sends radiation directly to cancer cells. The Swiss drugm...

Yahoo Finance 3d

Why Novartis Stock Topped the Market on Tuesday - Yahoo Finance

Scooting past analyst estimates for its latest quarter gave Novartis (NYSE: NVS) a lift on Tuesday. Investors like what they heard about the global healthcare c...

Analyst ratings

54%

of 26 ratings

Buy

34.6%

Hold

53.8%

Sell

11.5%

More NVS News

Benzinga 4d

FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors

FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors Tuesday, Novartis AG (NYSE:NVS) rece...

ABC News 4d

Novartis, Danaher rise; Nucor, Cadence Design Systems fall, Tuesday, 4/23/2024 - ABC News

Stocks that are trading heavily or have substantial price changes on Tuesday: Novartis, Danaher rise; Nucor, Cadence Design Systems fall The Associated Press...

Seeking Alpha 4d

Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results - Seeking Alpha

mohd izzuan/iStock via Getty Images Novartis (NYSE:NVS) is off to a strong start in 2024 with a $0.12 EPS beat and a $330 million revenue beat. The year-over-y...

Yahoo Finance 4d

The Zacks Analyst Blog Highlights Novartis, American Express, ConocoPhillips, Netflix and Schlumberger - Yahoo Finance

For Immediate Release Chicago, IL – April 23, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research a...

Investor's Business Daily 4d

Novartis Extends Three-Day Stock Sprint With First-Quarter Beat And Raise

Novartis (NVS) stock popped early Tuesday after the Swiss drugmaker reported core profit of $1.80 per share and $11.83 billion in first-quarter sales. X On av...

Benzinga 4d

Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook

Loading... Loading... Shares of Swiss pharma giant Novartis AG NVS after the company raised its full-year guidance following better-than-expected first-quarter...

TipRanks 4d

Novartis Q1 Results Surge, 2024 Outlook Brightens - TipRanks.com - TipRanks

Novartis AG (NVS) has released an update. Novartis AG has reported a robust start to 2024 with double-digit sales growth and a significant expansion of core ma...